Psoriasis - Pipeline Insight, 2021

This “Psoriasis - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Psoriasis Understanding

Psoriasis: Overview

Psoriasis is a chronic inflammatory skin disorder that is accompanied with various clinical manifestations and is caused due to the involvement of genetic, environmental, and immunological factors (Rendon & Schäkel, 2019). It is a non-contagious dermatosis disease affecting almost 2% of the world population. It can be observed in the form of recurring red and scaly skin plaques that can be prominently differentiated from the normal adjacent skin. The physical and psychological impact of psoriasis can be well-compared with those of diabetes, depression, heart disease and cancer. The percentage of body affected by psoriasis can vary on an individual basis. It is possible to observe mild (10%) psoriasis in different people, however the most commonly witnessed psoriasis is chronic plaque psoriasis or psoriasis vulgaris. It is a chronic inflammatory skin disorder in which the dendritic cells, T lymphocytes, macrophages, neutrophils, and keratinocytes lead to skin lesions.

"Psoriasis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Psoriasis pipeline landscape is provided which includes the disease overview and Psoriasis treatment guidelines. The assessment part of the report embraces, in depth Psoriasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve Psoriasis.

Psoriasis Emerging Drugs Chapters

This segment of the Psoriasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Psoriasis Emerging Drugs

Bimekizumab: UCB

Bimekizumab (formerly UCB4940) is a novel humanized monoclonal antibody of the immunoglobulin G1 isotype, rationally designed to be able to bind at a similar site on both proinflammatory cytokine interleukin (IL)-17A and IL-17F, conveying dual inhibition of both isoforms. It is currently in preregistration stage for the treatment of Plaque psoriasis.

ABP 654: Amgen

ABP 654 (ustekinumab) is a biosimilar candidate to reference product STELARA. It is a monoclonal antibody that inhibits IL-12 and IL-23. Amgen is evaluating ABP 654 in Phase III clinical studies for the treatment of Inflammation (Plaque psoriasis).

MP1032: MetrioPharm

MP1032 belongs to a new class of anti-inflammatory drugs that act as potent ROS scavengers. A unique feature of this compound class is that the scavenging activity is dynamically regulated by an intracellular feedback loop. Scavenging activity increases with increased inflammatory activation of innate immune cells and ceases at physiological, non-inflammatory activation states. It is currently in phase 2 of development stage for the treatment of Plaque psoriasis.

Rimegepant: Biohaven Pharmaceuticals

Biohaven's Nurtec ODT (rimegepant) Received FDA Approval in February 2020. Nurtec ODT is the first and only CGRP receptor antagonist available in an orally disintegrating tablet (ODT) for the acute treatment of migraine, and the only oral CGRP receptor antagonist with product label claims including return to normal functioning and sustained durability of efficacy up to 48 hours after a single dose. It is currently in phase 2 of development stage for the treatment of Plaque psoriasis.

JTE-451: Akros Pharma

JTE 451 is a small molecule antagonists for the orphan nuclear receptor ROR? (nuclear receptor subfamily 1 group F member 3 antagonist), being developed by Japan Tobacco, as an oral formulation for the treatment of autoimmune and allergic disorders.

GR-MD-02: Galectin Therapeutics

GR-MD-02 (belapectin) is an inhibitor of galectin. It binds to galectin-3 proteins and disrupts its function. Belapectin is the first drug in a large, randomized clinical trial to demonstrate a clinically meaningful improvement in portal hypertension or liver biopsy in patients with NASH cirrhosis without varices.

ESR-114: Escalier Biosciences

ESR-114 topical gel is a selective, potent inhibitor of ROR?t designed to have its pharmacological activity targeted to the skin with minimal systemic absorption. ESR-114 topical gel is currently being evaluated to determine if it may reduce or treat the clinical manifestations of psoriasis. It is currently in phase 1/2 of development stage for the treatment of Plaque psoriasis.

Psoriasis: Therapeutic Assessment

This segment of the report provides insights about the different Psoriasis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Psoriasis

There are approx. 100+ key companies which are developing the therapies for Psoriasis. The companies which have their Psoriasis drug candidates in the most advanced stage, i.e. preregistration include, UCB.

Phases

This report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intramuscular
• Transdermal
• Topical.
• Intravenous
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Psoriasis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Psoriasis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Psoriasis drugs.

Psoriasis Report Insights

• Psoriasis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Psoriasis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Psoriasis drugs?
• How many Psoriasis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Psoriasis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Psoriasis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Psoriasis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Arcutis Biotherapeutics
• Sinocelltech Ltd.
• FYB202 GmbH & Co. KG
• Celltrion
• Coherus BioSciences
• Janssen Pharmaceuticals
• Can-Fite Biopharma
• Arcutis Biotherapeutics, Inc.
• Amgen
• GlaxoSmithKline
• Galectin Therapeutics Inc.
• Evelo Biosciences, Inc.
• Galderma R&D
• BioMimetix JV, LLC
• Boehringer Ingelheim
• Aurigene Discovery Technologies Limited
• AnaptysBio, Inc.
• AmDerma
• Akeso
• Affibody
• Menlo Therapeutics Inc.
• Aristea Therapeutics
• UNION Therapeutics
• MetrioPharm AG
• Provectus Pharmaceuticals
• Sienna Biopharmaceuticals
• Santalis Pharmaceuticals
• Atridia Pty Ltd.
• Dr. Reddy's Laboratories Limited
• Galderma R&D
• AB Science
• Lycera Corp.
• LEO Pharma
• Kadmon Corporation, LLC
• Akros Pharma Inc.
• Athenex
• DelArrivo
• Theramab LLC
• AbbVie
• AstraZeneca
• Immunic
• Bio-Thera Solutions
• CSL Behring
• Palobiofarma
• SFA Therapeutics
• NeuClone
• Galapagos NV
• Boston Pharmaceuticals
• Cellenkos
• Sareum
• Temisis Therapeutics
• Dice Molecules
• Aclaris Pharma
• Midatech Pharma
• Xbrane Biopharma

Key Products

• Roflumilast
• SCT630
• FYB202
• CT-P43
• CHS-1420
• Guselkumab
• Piclidenoson
• ARQ-154
• ABP 654
• GSK2982772
• GR-MD-02
• EDP1815
• CD10367
• BMX-010
• BI 730357
• AUR 101
• AM001
• AK101
• ABY-035
• Serlopitant
• RIST4721
• UNI-50001
• MP1032
• UHE-105
• Topical Rose Bengal
• SNA-120
• SAN021
• SHR-1314
• PPC-06
• PF-07038124
• NP000888
• Masitinib
• LYC-30937-EC
• LEO 22811
• KD025
• JTE-451
• Tirbanibulin
• DLX105-DMP
• TAB08
• ABBV-157
• AZD0284
• AK111
• IMU 935
• BAT2206
• CSL324
• PBF-1650
• SFA 002
• NeuLara
• GLPG3970
• BOS-475
• CK 0801
• SDC 1801
• TEM1657
• MTX114
• ATI-2138
• Xcimbane